| Company Name: |
LGM Pharma |
| Tel: |
1-(800)-881-8210 |
| Email: |
inquiries@lgmpharma.com |
2,4(1H,3H)-Pyrimidinedione, 5-ethynyl- (9CI) manufacturers
- Eniluracil
-
- $31.00
-
2026-05-26
- CAS:59989-18-3
- Purity: 99.91%
- Supply Ability: 10g
|
| | 2,4(1H,3H)-Pyrimidinedione, 5-ethynyl- (9CI) Basic information |
| | 2,4(1H,3H)-Pyrimidinedione, 5-ethynyl- (9CI) Chemical Properties |
| Melting point | 320° (dec) | | density | 1.527 | | storage temp. | under inert gas (nitrogen or Argon) at 2-8°C | | solubility | Soluble in DMSO | | form | solid | | pka | 7.44±0.10(Predicted) | | color | Yellow | | λmax | 284nm(MeOH)(lit.) | | Merck | 14,3584 | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
| | 2,4(1H,3H)-Pyrimidinedione, 5-ethynyl- (9CI) Usage And Synthesis |
| Description | Eniluracil (59989-18-3) is an irreversible dihydropyrimidine dehydrogenase (DPD) inhibitor.1-3 DPD is involved in the degradation of pyrimidine-based chemotherapeutic drugs such as 5-fluorouracil (5-FU). Eniluracil has been used along with 5-FU to prolong circulating concentrations of the drug. | | Uses | Potent inactivator of Dihydropyrimidine dehydrogenase (DPD). | | Definition | ChEBI: Eniluracil is a pyrimidone. | | in vivo | Eniluracil (5-Ethynyluracil) (1 mg/kg; i.p.; single daily for 3 days) exhibits neither toxicity nor intrinsic antitumor activity, and greatly improves FUra (5-fluorouracil) therapy in rats[1]. | Animal Model: | Female Fischer 344/HSD rats (6 to 7-week-old; 150-200 g)[1]. | | Dosage: | 1 mg/kg | | Administration: | Intraperitoneal injection; single daily for 3 days (l h before FUra (5-fluorouracil) and for an additional 2 days after FUra therapy) | | Result: | Produced complete tumor regression that was sustained for at least 90 days posttherapy when combined with 3.5 mg/kg FUra, however, 35 mg/kg FUra alone produced partial responses in 75% of the treated animals ( the tumors regrew in all of these animals). |
| | References | [1] D J PORTER. Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil.[J]. The Journal of Biological Chemistry, 1992, 267 8: 5236-5242.
[2] D P BACCANARI. 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil.[J]. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90 23: 11064-11068. DOI:10.1073/pnas.90.23.11064
[3] R L SCHILSKY H L K. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase.[J]. Expert opinion on investigational drugs, 2000, 9 7: 1635-1649. DOI:10.1517/13543784.9.7.1635 |
| | 2,4(1H,3H)-Pyrimidinedione, 5-ethynyl- (9CI) Preparation Products And Raw materials |
|